Asthma Therapeutics Market Size, Share & Trends Report

Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Anti- inflammatory, Bronchodilators), By Product (Inhalers, Nebulizers), By Routeof Administration (Oral, Inhaled), By Region, And Segment Forecasts, 2024 - 2030

Report ID: 978-1-68038-936-4
Number of Pages: 150
Format: Electronic (PDF)

Historical Range: 2018 - 2023
Industry: Healthcare

Market Segmentation

Asthma Therapeutics Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
- Anti-inflammatory
- Bronchodilators
- Combination Therapy
Asthma Therapeutics Product Outlook (Revenue, USD Billion, 2018 - 2030)
- Inhalers
  - Dry Powder
  - Metered Dose
  - Soft Mist
- Nebulizers
Asthma Therapeutics Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)
- Oral
- Inhaled
- Others
Asthma Therapeutics Regional Outlook (Revenue, USD Billion, 2018 - 2030)
- North America
  - North America Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
    - Anti-inflammatory
    - Bronchodilators
    - Combination Therapy
  - North America Product Outlook (Revenue in USD Billion, 2018 - 2030)
    - Inhalers
      - Dry Powder
      - Metered Dose
      - Soft Mist
    - Nebulizers
  - North America Rout of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
    - Oral
    - Inhaled
    - Others
  - U.S.
    - U.S. Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - U.S. Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - U.S. Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Canada
    - Canada Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Canada Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Canada Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
- Europe
  - Europe Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
    - Anti-inflammatory
    - Bronchodilators
    - Combination Therapy
  - Europe Product Outlook (Revenue in USD Billion, 2018 - 2030)
    - Inhalers
    - Dry Powder
    - Metered Dose
    - Soft Mist
    - Nebulizers
  - Europe Rout of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
    - Oral
    - Inhaled
    - Others
  - Germany
    - Germany Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Germany Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Germany Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - UK
    - UK Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - UK Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - UK Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - France
    - France Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - France Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - France Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Italy
    - Italy Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Italy Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Italy Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Spain
    - Spain Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Spain Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Spain Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Denmark
    - Denmark Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Denmark Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Denmark Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Sweden
    - Sweden Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Sweden Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Sweden Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Norway
    - Norway Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Norway Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Norway Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
- Asia Pacific
  - Asia Pacific Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
    - Anti-inflammatory
    - Bronchodilators
    - Combination Therapy
  - Asia Pacific Product Outlook (Revenue in USD Billion, 2018 - 2030)
    - Inhalers
      - Dry Powder
      - Metered Dose
      - Soft Mist
    - Nebulizers
  - Asia Pacific Rout of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
    - Oral
    - Inhaled
    - Others
  - Japan
    - Japan Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Japan Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Japan Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - China
    - China Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - China Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - China Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - India
    - India Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - India Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - India Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - South Korea
    - South Korea Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - South Korea Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - South Korea Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Australia
    - Australia Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Australia Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Australia Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Thailand
    - Thailand Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Thailand Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Thailand Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
- Latin America
  - Latin America Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
    - Anti-inflammatory
    - Bronchodilators
    - Combination Therapy
  - Latin America Product Outlook (Revenue in USD Billion, 2018 - 2030)
    - Inhalers
      - Dry Powder
      - Metered Dose
      - Soft Mist
    - Nebulizers
  - Latin America Rout of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
    - Oral
    - Inhaled
    - Others
  - Brazil
    - Brazil Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Brazil Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Brazil Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Mexico
    - Mexico Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Mexico Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Mexico Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Argentina
    - Argentina Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Argentina Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Argentina Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
- Middle East and Africa
  - Middle East and Africa Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
    - Anti-inflammatory
    - Bronchodilators
    - Combination Therapy
  - Middle East and Africa Product Outlook (Revenue in USD Billion, 2018 - 2030)
    - Inhalers
      - Dry Powder
      - Metered Dose
      - Soft Mist
    - Nebulizers
  - Middle East and Africa Rout of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
    - Oral
    - Inhaled
    - Others
  - South Africa
    - South Africa Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - South Africa Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - South Africa Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Saudi Arabia
    - Saudi Arabia Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Saudi Arabia Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Saudi Arabia Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - UAE
    - UAE Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - UAE Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - UAE Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others
  - Kuwait
    - Kuwait Drug Class Outlook (Revenue in USD Billion, 2018 - 2030)
      - Anti-inflammatory
      - Bronchodilators
      - Combination Therapy
    - Kuwait Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Inhalers
        
        Dry Powder
        
        Metered Dose
        
        Soft Mist
      - Nebulizers
    - Kuwait Route of Administration Outlook (Revenue in USD Billion, 2018 - 2030)
      - Oral
      - Inhaled
      - Others

Asia Pacific Flooring Market Dynamics

Driver: Increasing Incidence Of Asthma

The global increase in incidence of asthma has significantly raised the demand for therapeutics. Government and nongovernment organizations emphasize the rapid growth in asthma patients, labeling it a severe public health concern. High asthma prevalence in developed economies, such as the U.S., France, and Spain, is expected to drive demand & support overall market growth. The substantial impact of asthma is evident in the U.S., with ten daily asthma-related deaths in 2021 that were preventable with proper treatment. Notably, WHO reported 455,000 asthma-related deaths in 2019. There is a rapid growth in the incidence of asthma in the Asia Pacific and Europe. This underscores a potential surge in demand for asthma therapeutics, driving the market growth.

Driver: Emergence Of Novel Biologics

The rising incidence of uncontrolled asthma, despite the availability of suitable treatment options, has driven the demand for alternative & effective treatments. Existing asthma medications fall short of addressing frequent asthma attacks. Consequently, key companies are developing novel, effective biologic-based therapies designed with target-specific mechanisms, particularly monoclonal antibodies. Considered the most promising asthma treatment options, new therapies, including antiimmunoglobulin E (IgE) antibodies, cytokine modulators, and DNA vaccinations, are now utilized for uncontrolled asthma. The anti-Inge monoclonal antibody (ibalizumab) effectively treats severe allergic asthma. The introduction or approval of these new biologics is anticipated to reshape the asthma treatment landscape, boosting the market over the forecast period.

Restraint: Patent Expiration Of Branded Drugs

Frequent patent expiration of branded asthma drugs is restraining growth of the asthma therapeutics market. It is anticipated to negatively affect sales of branded drugs. For instance, Celltrion completed a marketing authorization application for CT-P39, a biosimilar of Xolair, with its substance patent already expired. The formulation patent is set to expire in March 2024 in Europe and November 2025 in the U.S. The expiry of patents, notably Xolair's formulation patent, restrains the asthma therapeutic market, causing heightened generic competition, price erosion, market saturation, loss of exclusivity, and challenges sustaining revenue & fostering innovation. Despite its blockbuster status with USD 5 trillion in global sales in 2022, the market faces limitations in growth and dynamics.

What Does This Report Include?

This section will provide insights into the contents included in this asthma therapeutics market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Asthma therapeutics market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Asthma therapeutics market quantitative analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.